AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
According to the American Heart Association, PAD affects 8.5 million Americans and 200 million people worldwide each year1.
- According to the American Heart Association, PAD affects 8.5 million Americans and 200 million people worldwide each year1.
- Studies have shown that radial access is associated with a significantly lower risk of major bleeding and access site complications when compared to femoral access2,3 in the treatment of patients.
- Use of a general radial access catheter may reduce incidents of major bleeding, when compared to femoral access, by more than 70%3.
- The technology underlying the Auryon Atherectomy System has been shown in clinical studies to be effective in treating lesions ranging from soft plaque to severely calcified5,6,8.